efaproxiral
information and resources from the National Cancer Institute
NCI Thesaurus | efaproxiral
A synthetic small molecule with radiosensitizing activity. Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to the hemoglobin tetramer and decreasing hemoglobin-oxygen binding affinity. Increasing tumor oxygenation reduces tumor radioresistance. NCI Thesaurus | efaproxiral
A synthetic small molecule with radiosensitizing activity. Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to the hemoglobin tetramer and decreasing hemoglobin-oxygen binding affinity. Increasing tumor oxygenation reduces tumor radioresistance.
|
|
|
|
news articles
Drug Tested To Stop Cancer From Spreading Mar 28, 2006
WBAL Channel.com, Researchers recently found a drug called efaproxiral, when combined with radiation therapy, may help women live several months longer by stopping or shrinking ...
Allos Therapeutics Reports 2005 Financial Results Mar 6, 2006
PR Newswire (press release), Product Portfolio Update: EFAPROXYN(TM) (efaproxiral): * ENRICH, the Company's pivotal Phase 3 study of EFAPROXYN in patients with brain metastases originating ...
Allos Therapeutics Reports 2005 Financial Results Mar 6, 2006
MSN Money The Company's lead product candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic small molecule designed to sensitize hypoxic, or oxygen-deprived, tumor ...
Retrospective Analysis Finds EFAPROXYN(TM) Extends Survival With ... Dec 12, 2005
PR Newswire (press release), ...announced the presentation of new findings from its Phase 3 clinical trial of the investigational radiation sensitizer EFAPROXYN(TM) (efaproxiral) in patients ...
PDX Shows Promising Activity in Patients With Resistant T-Cell ... Dec 12, 2005
PR Newswire (press release), The Company's lead product candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic small molecule designed to sensitize hypoxic, or oxygen-deprived, tumor ...
Allos Therapeutics Appoints Timothy P. Lynch to Board of Directors Nov 17, 2005
PR Newswire (press release), Our lead product candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic small molecule designed to sensitize hypoxic, or oxygen-deprived, tumor tissue during ...
|
|
